

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	1,456,700	1,524,800	1,586,300	1,646,500
Prediabetes	399,800	432,300	463,200	481,400
Diagnosed diabetes	101,100	125,300	146,600	164,300
Undiagnosed diabetes	41,100	48,400	53,700	57,000
Total with diabetes (diagnosed and undiagnosed)	142,200	173,700	200,300	221,300
Complications:				
Visual impairment	16,600	20,000	22,700	24,600
Renal failure	240	290	330	350
Leg amputations	210	240	260	260
Annual deaths attributable to diabetes	1,090	1,290	1,430	1,520
Total annual cost (2015 dollars)	\$1.7 B	\$2.1 B	\$2.4 B	\$2.6 B
Annual medical costs	\$1.2 B	\$1.5 B	\$1.7 B	\$1.9 B
Annual nonmedical costs	\$0.5 B	\$0.6 B	\$0.7 B	\$0.7 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	217,500	261,900	311,500	352,800
Prediabetes	110,900	133,500	158,800	179,900
Diagnosed diabetes	41,100	49,500	58,900	66,700
Undiagnosed diabetes	15,200	18,300	21,800	24,700
Total with diabetes (diagnosed and undiagnosed)	56,300	67,800	80,700	91,400
Complications:				
Visual impairment	7,700	9,000	10,500	11,500
Renal failure	130	150	170	190
Leg amputations	95	110	120	120
Annual deaths attributable to diabetes	750	860	930	960
Total annual cost (2015 dollars)	\$720 M	\$866 M	\$1.0 B	\$1.2 B
Annual medical costs	\$675 M	\$812 M	\$0.9 B	\$1.1 B
Annual nonmedical costs	\$45 M	\$54 M	\$0.1 B	\$0.1 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.